Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

139.37 -3.82 (-2.67%)
Streaming Delayed Price Updated: 1:49 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 237,228
Open 143.50
Bid (Size) 139.28 (2)
Ask (Size) 139.47 (2)
Prev. Close 143.19
Today's Range 139.03 - 143.54
52wk Range 93.02 - 148.37
Shares Outstanding 100,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
The market rally appears to be picking up steam. 
Via Investor's Business Daily
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. 
Via Investor's Business Daily

Performance

YTD
+5.80%
+5.80%
1 Month
-0.05%
-0.05%
3 Month
-2.51%
-2.51%
6 Month
+19.45%
+19.45%
1 Year
+42.36%
+42.36%

More News

Read More
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
Via Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
Via Chartmill
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
Via Investor's Business Daily
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
Via Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Via Investor's Business Daily
3 Red-Hot Biotech Rockets Blasting Off in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Via Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
Via Investor's Business Daily
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
The 5 Stocks Most Sold By Insiders This Year
Via MarketBeat
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Via Chartmill
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Via Chartmill
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.